Why the Up-C Structure Is a Good Alternative Route to an IPO

The umbrella partnership C corporation (Up-C) structure has been a popular option for pass-through entities looking to gain access to the capital markets.

More

Navigating SEC Comment Letters: Non-GAAP Disclosures and Metrics

Inevitably, companies looking to go public will face the prospect of comment letters from the Securities and Exchange Commission (SEC).

More

The Ultimate Guide to a Life Sciences IPO

The life sciences industry is in the middle of an IPO boom, with the 10 highest-valued biotech IPOs raising $3.

More

Get Ahead of Your Next Audit by Implementing ASC 606 Revenue Recognition Standards

Time is running out for any remaining companies to implement the latest ASC 606 revenue recognition standard.

More

The Future Is Already Here, and CFOs Need to Transform Finance to Survive

Download the Whitepaper

Meet Kelly Provost: A Leader in CFGI’s Life Sciences Capital Markets

Kelly Provost is a leader in CFGI’s Life Sciences Capital Markets practice and has dedicated her career to supporting companies that are trying to cure diseases and save lives, making a difference in the lives of people across the world.

More

How to Get Paid for Transformation (Shhh, Without Doing It All!)

The sell-side quality-of-earnings (QoE) report has become a critical piece of any private equity transaction.

More

Navigating SEC Comment Letters: Segment Reporting

When companies are ready to go public, they’re often surprised by the increased reporting demands during and following the period of transition from a private entity.

More

Meet Angela Barcelos: CFGI’s Risk Advisory Practice Leader

Through hard work and dedication, Angela Barcelos has made a name for herself at CFGI and in the broader financial industry.

More